Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer

British Journal of Cancer

Volumn 93, Issue 7, 2005, Pages 799-803

  Sakakibara, T ^a   Hibi, K ^a   Koike, M ^a   Fujiwara, M ^a   Kodera, Y ^a   Ito, K ^a   Nakao, A ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Plasminogen activator inhibitor 1; Quantitative RT PCR

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CANCER STAGING; COLORECTAL CANCER; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 27144449936     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602743     Document Type: Article

References (35)

1. Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S (1999) Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 86: 2602-2611
2. Bajou K (2002) Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis]. Bull Mem Acad Roy Med Belg 157: 313-318
3. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A (2004) Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23: 6986-6990
4. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4: 923-928
5. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915
6. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297
7. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, Korc M, Buchler MW (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75: 388-395
8. Castello R, Estelles A, Vazquez C, Falco C, Espana F, Almenar SM, Fuster C, Aznar J (2002) Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin Chem 48: 1288-1295
9. Chambers SK, Ivins CM, Carcangiu ML (1998) Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79: 449-454
10. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS (1997) High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 79: 878-883
11. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart JM (2002) The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16: 147-154
12. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130-135
13. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636-643
14. Folkman J, Browder T, Palmblad J (2001) Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86: 23-33
15. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
16. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ (2000) Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60: 5839-5847
17. Hibi K, Nakamura H, Hirai A, Fujikake Y, Kasai Y, Akiyama S, Ito K, Takagi H (1996) Loss of H19 imprinting in esophageal cancer. Cancer Res 56: 480-482
18. Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A (2004) CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. Br J Cancer 90: 1030-1033
19. Hibi K, Nakayama H, Koike M, Kasai Y, Ito K, Akiyama S, Nakao A (2002) Colorectal cancers with both p16 and p14 methylation show invasive characteristics. Jpn J Cancer Res 93: 883-887
20. Hibi K, Taguchi M, Nakamura H, Hirai A, Fujikake Y, Matsui T, Kasai Y, Akiyama S, Ito K, Takagi H (1997) Alternative splicing of the FHIT gene in colorectal cancers. Jpn J Cancer Res 88: 385-388
21. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H (1991) Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6: 2291-2296
22. Knoop A, Andreasen PA, Andersen JA, Hansen S, Laenkholm AV, Simonsen AC, Andersen J, Overgaard J, Rose C (1998) Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77: 932-940
23. Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M (2001) Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 7: 1743-1749
24. Lijnen HR (2005) Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3: 35-45
25. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964-33968
26. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907
27. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253: 665-669
28. Pasco JA, Henry MJ, Kotowicz MA, Collier GR, Ball MJ, Ugoni AM, Nicholson GC (2001) Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 86: 1884-1887
29. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675
30. Potempa J, Korzus E, Travis J (1994) The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 269: 15957-15960
31. Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A (2004) Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res 10: 1375-1378
32. Umeda T, Eguchi Y, Okino K, Kodama M, Hattori T (1997) Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 183: 388-397
33. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532
34. Wang EJ, Kripke DF, Stein MT, Parry BL (2003) Measurement of illumination exposure in postpartum women. BMC Psychiatry 3: 5
35. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A (2002) PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 8: 192-195